Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Classifying Malignancy in Prostate Glandular Structures From Biopsy Scans With Deep Learning

Classifying malignancy in prostate glandular structures from biopsy scans with deep learning

Authors: Fogarty R, Goldgof D, Hall L, Lopez A, Johnson J, Gadara M, Stoyanova R, Punnen S, Pollack A, Pow-Sang J, Balagurunathan Y

Cancers (Basel). 2023 Apr 17;15(8):2335. doi: 10.3390/cancers15082335

Specialties: Oncology

Related content

Publication
Radiotherapy Before or During Androgen-Deprivation Therapy Does Not Blunt the Exercise-Induced Body Composition Protective Effects in Prostate Cancer Patients: A Secondary Analysis of Two Randomized Controlled Trials

Related content

Publication
Radiotherapy Before or During Androgen-Deprivation Therapy Does Not Blunt the Exercise-Induced Body Composition Protective Effects in Prostate Cancer Patients: A Secondary Analysis of Two Randomized Controlled Trials
Publication
A Pilot Feasibility Study of Digital Health Coaching for Men With Prostate Cancer

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.